Immediate Impact
3 from Science/Nature 55 standout
Citing Papers
A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the iron-ornithine axis
2024 Standout
Advances and challenges in therapeutic targeting of NRF2
2023 Standout
Works of Kyle Smoot being referenced
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)
2018
Real-World Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis Patients who Switch from Natalizumab to Delayed-Release Dimethyl Fumarate: A Multicenter, Retrospective, Observational Study (STRATEGY) (P3.293)
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Kyle Smoot | 139 | 71 | 91 | 101 | 20 | 311 | |
| Lorenzo De Santi | 130 | 34 | 78 | 96 | 16 | 319 | |
| R. Gold | 113 | 46 | 79 | 66 | 22 | 345 | |
| Christian Sindic | 119 | 49 | 94 | 68 | 25 | 355 | |
| Bo Sun | 178 | 43 | 226 | 45 | 20 | 363 | |
| Souraya El Sankari | 213 | 33 | 104 | 40 | 19 | 338 | |
| Sanaz Ahmadi Karvigh | 70 | 27 | 58 | 49 | 18 | 325 | |
| Mohammad Reza Motamed | 68 | 19 | 75 | 40 | 25 | 307 | |
| A Ridley | 60 | 24 | 96 | 61 | 23 | 341 | |
| Xueping Zheng | 52 | 26 | 43 | 37 | 24 | 311 | |
| Joshua Barton | 279 | 27 | 108 | 35 | 21 | 355 |
All Works
Loading papers...